Regeneron’s cemdisiran for AChR-antibody positive and argenx’s efgartigimod for AChR-antibody negative generalized myasthenia gravis met key endpoints in phase 3 testing.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/positive-topline-data-could-expand-myasthenia-gravis-therapy-2025a1000mna?src=rss
Author :
Publish date : 2025-08-27 16:44:00
Copyright for syndicated content belongs to the linked Source.
